Shares of Regeneron Pharmaceuticals Inc. (REGN) surged 2.6% in premarket trading on Thursday, reaching a 5-week high. The biotechnology company announced its second-quarter profit and revenue, which exceeded expectations, primarily driven by robust collaboration revenue.
Impressive Financial Performance
Regeneron reported a net income of $968.4 million, or $8.50 per share, compared to $852.1 million, or $7.47 per share, in the same period last year. Adjusted earnings per share reached $10.24, surpassing the FactSet consensus of $9.88. Additionally, revenue witnessed a growth of 10.5% to $3.16 billion, outperforming the FactSet consensus of $3.02 billion.
Strong Collaboration Revenue
The company's collaboration revenue experienced a significant surge of 26.2% to $1.32 billion, while product sales rose by 1% to $1.77 billion. Notably, sales of their wet age-related macular degeneration treatment, Eylea, incurred a decline of 7.5% to $1.50 billion due to intensified competition and changing market dynamics resulting in lower selling prices.
Market Performance
Regeneron's stock has gained 1.5% year-to-date through Wednesday, performing favorably amid challenging market conditions. Meanwhile, the S&P 500 has rallied 17.6%, underscoring Regeneron's resilience and ability to deliver promising results even during turbulent times.
Regeneron Pharmaceuticals Inc.’s outstanding second-quarter performance highlights its strength in collaboration revenue and ability to navigate competitive challenges effectively, positioning the company for continued growth and success in the biotechnology sector.
More Articles
All Rights Reserved © 2024
Post a comment